Medical Technology and Devices (MTD) is pleased to announce the successful completion of the strategic acquisition of the Ypsomed pen needles and blood glucose monitoring (BGM) business units, which was announced at the end of March. This acquisition is an important step in MTD’s mission to provide world-class solutions for the treatment of diabetes and obesity on a global scale.
Strengthen our position as number 2 in the world by increasing production capacity to over 2.5 billion pen needles
With this acquisition, MTD strengthens its position as the clear number two in the world market for pen needles. This strategic acquisition not only reinforces our leadership position in diabetes care, but also reinforces our commitment to delivering innovative solutions for both self-care and professional practice. We will integrate Ypsomed pen needles into our European production and sales network, increasing our total production capacity to more than 2.5 billion pen needles.
A unique package designed to provide comprehensive coverage to more patients, consumers and healthcare professionals
The integration of Ypsomed’s businesses brings a wealth of advanced technologies and brands to MTD’s diabetes and obesity portfolio and complements our current product offering, which includes the G34, the pen needle thinnest and shortest on the market. Strengthening with this benefit MTD maintains its unique position by being able to offer a complete range of 3, 5 and 6 grind pen needles, click technology for easy and secure fitting, as well as single and double protection in safety pen needles. In addition, we recently launched continuous blood glucose monitoring (CGM) systems, winning tenders in Italy, marking our entry into this sector this year. This unique diabetes care package reinforces our ongoing commitment to innovation in professional and private healthcare. It includes sharp medical instruments such as the blood collection safety needle, veterinary catheter and the new passive safety needle, Protective picture. In addition, new blood pressure monitors, inhalers, foot care products and insect repellants will be launched in 2024.
Reaching 3 billion new users by entering the Chinese and Indian markets
The acquisition provides access to strategic high-growth markets such as China and India while strengthening our presence in established markets such as North America, Germany and the France. This expansion is a critical step for MTD as we look to expand our global reach and influence in the diabetes industry.
Invest in a modern production facility
As part of its continuous growth and development strategy, MTD is implementing a major investment plan to create the most competitive pen and lancet needle manufacturing facilities in Europe. These investments aim to increase capacity and further improve the performance, quality and ESG performance of our manufacturing operations.
“The completion of this building is a great moment for MTD Group. By merging the business areas of Ypsomed pen needles and blood glucose meters, we are consolidating our position as a leading supplier of diabetes care in the world and establishing ourselves as the second largest manufacturer of pen needles on around the world. This strategic move strengthens our ability to deliver high quality innovative solutions to our customers and expands our reach in key markets. Our significant investments reinforce our commitment to efficiently scale our operations while maintaining the highest quality standards. We are excited about the opportunities this acquisition presents and remain committed to advancing the future of diabetes care,” Charles Bouaziz Glic, CEO of MTD Group.
MTD was assisted by Studio Legale LCA for the legal aspects, with Roberto de Bonis, Sara Consoli and Mario Niggeler involved.
Information about MTD Group Inc
“Empower everyone to take control of their health, from start to finish, through intuitive monitoring, pain-free medication delivery, and easy-to-use solutions for everyday aches and pains.”
Medical Technology and Devices (MTD) is a consumer health group with a portfolio of global brands leading in diabetes, medical devices, wound care, heart monitors, thermometers and nebulizers. MTD owns Pic Solution in EMEA/APAC and Droplet in North America, iconic brands with over 40 years of history and 90% consumer recognition. The product portfolio is distributed in more than 100 markets – reaching half of the world’s population – thanks to direct branches in Italy, the USA, France, Germany and India, as well through a long-term dealer network in the rest of the world. . MTD has an extensive research and development department that develops and studies the most innovative technologies to meet the rapidly changing needs of consumers and healthcare professionals. Production takes place in a modern production system with 4 production sites across Europe. The group was created in 2018 from the merger of Pikdare and HTL Strefa and is based in Milan, Italy. The company is led by an international management team and has approximately 1,400 employees.
Logo: https://mma.prnewswire.com/media/2469174/4829787/MTD_Logo.jpg
